United States, Intermediary
Change
Showing
of
Insights Posts
Video
2 min
Collaboration in practice: Late-stage biotech
Nilesh Kumar, Head of Biotech Private Investing, explores how working with Wellington’s public-market biotech experts helps his team better understand the feasibility of emerging biotech innovations.
2 min
Video
2026-09-30
Video
3 min
Private biotech innovation versus hype
Nilesh Kumar discusses the next generation of biotech disruptors in obesity, autoimmunity, and oncology, focusing on drugs that solve real-world unmet medical needs.
3 min
Video
2026-06-30
Article
6 min
Private biotech market update: IPOs, M&A, and innovation
Our biotech venture capital experts explore the state of the private biotech market, highlighting the potential IPO-market rebound, surge in private M&A, and the focus on clinical-stage opportunities.
6 min
Article
2026-04-29
Video
4 min
Private biotech investing in 2025
Nilesh Kumar, head of biotech private investing, shares his outlook for 2025, weighing headline risk against biotech venture capital's potential tailwinds.
4 min
Video
2026-02-28
Article
5 min
Private biotech: Immunology and inflammation’s third wave
Our experts discuss how I&I is building on industry progress to offer new treatment solutions and interesting opportunities for private biotech investors.
5 min
Article
2025-12-01
Article
7 min
Venture capital outlook for 2025: 5 key trends
Our venture capital experts are encouraged by the healthier environment for venture capital in 2025. In this year's outlook, they explore key themes for the year ahead, including: higher deployment, AI, rebounding IPOs, and impacts of the 2024 election.
7 min
Article
2025-12-31
Article
4 min
Biotech IPOs in 2025: Quantity, quality, and best practices
We explore today's biotech IPO market, highlighting recent market trends, key characteristics for successful biotech IPOs, and best practices to sustain momentum as a public biotechnology company.
4 min
Article
2025-08-31
Article
10 min
Innovation and M&A driving biotech recovery
We are optimistic that the biotech market will continue to recover, supported by innovation, an improving macroeconomic environment, continued M&A activity, and improved fundamentals for the sector.
10 min
Article
2025-04-30
URL References
Related Insights